Roivant Sciences (ROIV) Insider Manchester Sells $28M of Stock

Insider Buying and Selling at Roivant Sciences Ltd.

Keith Manchester sold 800,000 shares of Roivant Sciences Ltd. (ROIV) on June 29, 2026, for a total of approximately $27.64 million. This sale occurred at an average price of $34.55 per share, just under the stock's closing price of $35.39 on the day of the transaction.

Recent Insider Activities

In addition to Manchester's sale, several other insiders made recent trades at Roivant. On June 30, both Qvt Financial LP and Gold Daniel Allen sold 12,380 shares of the company at $35.28 each, valued at about $436,766. Earlier, Mayukh Sukhatme, the President & CIO, sold 500,000 shares for $17.07 million on June 25. He also exercised options for another 500,000 shares at a lower price, indicating a mix of trading strategies among the firm's leadership. Eric Venker, the President & Immunovant CEO, was involved in multiple transactions too, including purchasing and selling shares just days apart.

Stock Performance Context

Roivant Sciences' shares recently traded at $35.39, below its 50-day moving average of $36.26. The stock has a 52-week high of $42.50 and a low of $14.50. The timing of these insider trades comes as the company prepares for its next earnings report on November 9, 2026. Market watchers may be assessing how these sales align with the company's performance and future prospects.

Analysts Set New Price Targets

Analysts are largely optimistic about Roivant Sciences. On October 12, 2026, Wolfe Research downgraded the stock to a 'Peer Perform' rating. However, firms like Stifel and TD Cowen maintained 'Buy' ratings, with price targets of $51.00 and $55.00, respectively. Overall, the consensus rating is a 'strong buy' based on 12 analyst opinions, with a mean price target of $47.79, suggesting room for growth.

What Roivant Sciences Ltd. Does

Roivant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines and technologies. With a strong pipeline targeting various diseases, including autoimmune conditions and pulmonary hypertension, the recent insider sales add to an interesting narrative for investors watching the company's developments.

What's Ahead for Roivant Sciences Ltd.

As Roivant approaches its earnings date on November 9, analysts and investors will be keen to see how the company’s recent activities, including insider sales and market performance, influence upcoming results. Remember, the insider trades reflect past positions and may not indicate current intentions, as seen in the significant transactions occurring around the same time.